Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Gamma Communications

(Sharecast News) - Analysts at Berenberg lowered their target price on communication services and solutions provider Gamma Communications from 2,000.0p to 1,570.0p on Friday as it said macro pressures on UK SMEs had forced it to lower forecasts. Berenberg said following Gamma Communications' annual general meeting trading update in May, it had reiterated its 'buy' rating on the stock but had opted to lower its DCF-based price target. However, Berenberg noted that its new target price still offered an "attractive" potential share price upside of roughly 31%.

"We cut our group EPS five-year CAGR forecast to 9% from 11%, driven by our expectation of lower organic growth in the UK Business division," said the German bank.

"We continue to expect a valuation re-rating in the Gamma shares from current levels (trading at 13x P/E and 8x EV EBITDA). We still believe there is further share price upside potential from more value-accretive M&A or additional shareholder distributions given headroom provided by Gamma's strong FCF generation (c8% FCF yield) and under-leveraged balance sheet."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.